Q1 2024

Filed May 14, 2024 · 10-Q · 44 days after period end · 0001477932-24-002788

Q1 2024 · 10-Q

Revenue

$6.00K

−72.7% vs Q1 2023

Net Income

-$402.00K

N/M vs Q1 2023

EPS Diluted

-$0.01

N/M vs Q1 2023

Gross Profit$4,000−69.2%

Operating Income

Same quarter

Metric	Q1 2024	Q1 2023	Q1 2022	Q1 2021
Revenue	$6.00K	$22.00K	$5.00K	$0.00
Net Income	-$402.00K	-$869.00K	-$507.00K	-$603.00K
EPS Diluted	-$0.01	-$0.02	-$0.05	-$0.04

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Guided Therapeutics Inc · CIK 924515 · Engraved from SEC EDGAR